Novartis AG has identified spirocyclic piperidinyl derivatives acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration (AMD), diabetic retinopathy and eye disorders.
Terran Biosciences Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of anxiety, Alzheimer's disease, stroke, rheumatoid arthritis, neurodegeneration, mood disorders, menopause, substance abuse and dependence, among others.
Researchers from Shandong University and colleagues presented the characterization of [I] as the most active compound from a series of novel diarypyridimine derivatives intended to overcome resistance to NNRTI-resistant HIV-1 strains. The compound displayed EC50 values of 0.0010 and 0.18 µM against HIV IIIB and RES056 strains, respectively.
Oncusp Therapeutics Inc. has received IND clearance from the FDA to begin clinical trials with CUSP-06, a cadherin-6 (CDH6)-targeting antibody-drug conjugate designed for the treatment of multiple solid tumors. CDH6 is overexpressed in cancers including ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma. A phase I trial will pave the way for expansion in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Artiva Biotherapeutics Inc. has received FDA clearance of its IND application for Allonk (AB-101), to be used in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis.
Interleukin-4 (IL-4) plays an important role in regulating inflammation. While several antibody-based options targeting IL-4 have been reported, strategies based on small molecule inhibitors have proven difficult to find.
RSS
